1-5 of 5
Nancy K. Pryer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

PCA062, a P-cadherin Targeting Antibody–Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin–expressing Malignancies

Qing Sheng, Joseph A. D'Alessio, Daniel L. Menezes, Christopher Karim, Yan Tang, Angela Tam, Suzanna Clark, Chi Ying, Anu Connor, Keith G. Mansfield, Jean-Michel Rondeau, Majid Ghoddusi, Felipe C. Geyer, Jane Gu, Margaret E. McLaughlin, Rick Newcombe, GiNell Elliot, William R. Tschantz, Sylvie Lehmann, Christie P. Fanton, Kathy Miller, Thomas Huber, Katherine G. Rendahl, Ursula Jeffry, Nancy K. Pryer, Emma Lees, Paul Kwon, Judith A. Abraham, Jason S. Damiano, Tinya J. Abrams
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (7): 1270–1282.
https://doi.org/10.1158/1535-7163.MCT-20-0708
Published: 01 July 2021
View article titled, PCA062, a P-cadherin Targeting Antibody–Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin–expressing Malignancies
Open the PDF for PCA062, a P-cadherin Targeting Antibody–Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin–expressing Malignancies in another window
Includes: Supplementary data
Journal Articles

The Novel Oral Hsp90 Inhibitor NVP-HSP990 Exhibits Potent and Broad-spectrum Antitumor Activities In Vitro and In Vivo

Daniel L. Menezes, Pietro Taverna, Michael R. Jensen, Tinya Abrams, Darrin Stuart, Guoying Karen Yu, David Duhl, Timothy Machajewski, William R. Sellers, Nancy K. Pryer, Zhenhai Gao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (3): 730–739.
https://doi.org/10.1158/1535-7163.MCT-11-0667
Published: 06 March 2012
View article titled, The Novel Oral Hsp90 Inhibitor NVP-HSP990 Exhibits Potent and Broad-spectrum Antitumor Activities <em>In Vitro</em> and <em>In Vivo</em>
Open the PDF for The Novel Oral Hsp90 Inhibitor NVP-HSP990 Exhibits Potent and Broad-spectrum Antitumor Activities <em>In Vitro</em> and <em>In Vivo</em> in another window
Includes: Supplementary data
Journal Articles

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts

David W. Fry, Patricia J. Harvey, Paul R. Keller, William L. Elliott, MaryAnne Meade, Erin Trachet, Mudher Albassam, XianXian Zheng, Wilbur R. Leopold, Nancy K. Pryer, Peter L. Toogood
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2004) 3 (11): 1427–1438.
https://doi.org/10.1158/1535-7163.1427.3.11
Published: 01 November 2004
View article titled, Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts
Open the PDF for Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts in another window
Journal Articles

Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer

Tinya J. Abrams, Lesley J. Murray, Enrico Pesenti, Vicky Walker Holway, Tina Colombo, Leslie B. Lee, Julie M. Cherrington, Nancy K. Pryer
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2003) 2 (10): 1011–1021.
Published: 24 October 2003
View article titled, Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer
Open the PDF for Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer in another window
Journal Articles

SU11248 Inhibits KIT and Platelet-derived Growth Factor Receptor β in Preclinical Models of Human Small Cell Lung Cancer

Tinya J. Abrams, Leslie B. Lee, Lesley J. Murray, Nancy K. Pryer, Julie M. Cherrington
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2003) 2 (5): 471–478.
Published: 01 May 2003
View article titled, SU11248 Inhibits KIT and Platelet-derived Growth Factor Receptor β in Preclinical Models of Human Small Cell Lung Cancer
Open the PDF for SU11248 Inhibits KIT and Platelet-derived Growth Factor Receptor β in Preclinical Models of Human Small Cell Lung Cancer in another window